A Phase 2 interventional study of BI 811283 (d 1 and 15) and Cytarabine in Leukemia, Myeloid, Acute, sponsored by Boehringer Ingelheim. Completed at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-14.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.
Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 85th largest by enrollment of the 239 interventional ones that give a count, is one of 9 that started in 2008, is one of 112 in phase 2, and was the 72nd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Beijing 302 Hospital · Sites in China
Ages 18–70
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 1 mo–30 yrs
Fujian Medical University Union Hospital · Sites in China
Ages 14–60
By country, each count listing its studies:
Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 92 · Phase 2 156 · Phase 3 29 · Phase 4 3
First in 1993; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 48 across the 239 interventional studies. Of the 168 that completed or were terminated, 79 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 247 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 9 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
9 of the studies testing cytarabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT03330821University of Southern CaliforniaPevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | 2026-12-31 |
| NCT06621212First Affiliated Hospital of Zhejiang UniversityMitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
Drug: BI 811283 (d 1 and 15) · Drug: Cytarabine
BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
Drug: Cytarabine · Drug: BI 811283 (d1)
BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.
The MTD was defined as the highest dose at which 6 patients were treated and less than 2 patients who experienced a dose limiting toxicities (DLT) within the first cycle of treatment.The MTD was defined based on safety data from the first cycle only. It was determined using a standard "3 + 3 design with de-escalation".
Time frame: up to 28 days of treatment
Response (Complete Remission [CR], Complete Remission With Incomplete Blood Count Recovery [CRi])
Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria: The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. * Complete remission (CR): morphologically leukaemia free state (i.e. bone marrow with \< 5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥ 1,000/μL and platelets \> 100,000/μL. * Complete remission with incomplete blood count recovery ("incomplete" CR, CRi).All of the above criteria for CR had to be met, except that neutrophils \< 1,000/μL or platelets \< 100,000/μL in the blood.
Time frame: Data collected up to cut-off date 20Oct2011, Up to 1239 days
Incidence and Intensity of AEs Graded According to CTCAE (Version 3.0)
The severity and timing of AEs indicates how well the treatment regimen was tolerated. Toxicities were evaluated using the common terminology criteria for adverse events (CTCAE) grading scheme.
Time frame: Data from first treatment administration until cut-off date of 20 October 2011; up to 1239 days
Incidence of Dose Limiting Toxicity (DLT)
Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)
Time frame: up to 28 days of treatment
Partial Remission
Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria; The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. Partial remission (PR). All of the criteria for CR had to be met, except that the bone marrow had to contain ≥ 5% but less than 25% blasts (or ≤ 50% of initial blast count), or \< 5% blasts in the presence of Auer rods or abnormal morphology.
Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Event Free Survival (EFS)
EFS was defined as the duration of time from randomisation to time of treatment failure (i.e. PD), relapse from CR, or death from any cause, whichever came first.
Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Relapse Free Survival
Relapse-free survival was defined only for patients who achieved CR/CRi and was measured from the date of attaining CR/CRi until the date of recurrence or death from any cause, whichever occurred first. Number of patients having relapse free survival are presented.
Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Remission Duration
Remission duration analysis was defined only for patients who achieved CR, and was measured from the date of attaining CR until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of the cause.
Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Overall Survival (OS)
OS was defined for all patients that entered the trial, and measured from the date of randomization until death from any cause.
Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Cmax (Maximum Measured Concentration of BI 811283 in Plasma)
Cmax (maximum measured concentration of BI 811283 in plasma) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
AUC(0-inf) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
AUC0-tz (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
Cmax (maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State
AUC (0-inf, ss)(area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) at steady state during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State
AUC (0-tz,ss) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) at steady state during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)
tmax (time from dosing to maximum measured concentration of BI 811283 in plasma) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
tmax,ss (time from dosing to maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1
Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Cmax (Maximum Measured Concentration of Cytarabine in Plasma)
Cmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)
Tmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
AUC (0-inf) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
AUC (0-tz) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Pharmacodynamic Monitoring
Pharmacodynamic monitoring: drug effect on leukaemia cells (e.g. polyploidy, histone H3 phosphorylation, morphologic changes). An evaluation of this secondary endpoint is not possible due to missing samples / samples of poor quality of the provided material.
Time frame: On Day 5, i.e. 72 hours after the end of the first BI 811283 infusion, and on Day 28 in the first cycle only
Pharmacokinetics of Cytarabine After a Single Dose and at Steady State When Given Alone
The study protocol originally included a phase II part with a treatment arm in which Cytarabine was given alone, however the sponsor discontinued the clinical development of BI 811283, therefore the protocol was amended and the reference therapy arm was removed from the study protocol" -\> (Protocol Amendment 5, version 19 -May-2010, approved 28-Jun-2010). Since there was never a treatment arm in which Cytarabine was given alone; hence pharmacokinetics are not calculated.
Time frame: -0.05, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours
68 participants were entered, and 64 were treated with the study treatment
| Milestone | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283+ 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 5 | 3 | 4 | 7 | 8 | 5 | 4 | 5 | 3 | 7 | 4 | 3 | 6 |
| Treated | 4 | 3 | 3 | 4 | 7 | 7 | 4 | 4 | 5 | 3 | 7 | 4 | 3 | 6 |
| Not treated | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 5 | 3 | 4 | 7 | 8 | 5 | 4 | 5 | 3 | 7 | 4 | 3 | 6 |
| Withdrew: Progressive disease | 3 | 2 | 2 | 2 | 4 | 4 | 3 | 2 | 3 | 2 | 4 | 3 | 2 | 4 |
| Withdrew: Other adverse event | 1 | 1 | 1 | 1 | 2 | 4 | 1 | 2 | 2 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Refuse to continue medication | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason other than those specified above | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 2 |
The MTD was defined as the highest dose at which 6 patients were treated and less than 2 patients who experienced a dose limiting toxicities (DLT) within the first cycle of treatment.The MTD was defined based on safety data from the first cycle only. It was determined using a standard "3 + 3 design with de-escalation".
| mg | Treatment Schedule A | Treatment Schedule B |
|---|---|---|
| The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine. | 100 | NA |
Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria: The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. * Complete remission (CR): morphologically leukaemia free state (i.e. bone marrow with \< 5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥ 1,000/μL and platelets \> 100,000/μL. * Complete remission with incomplete blood count recovery ("incomplete" CR, CRi).All of the above criteria for CR had to be met, except that neutrophils \< 1,000/μL or platelets \< 100,000/μL in the blood.
| participants | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| CRi | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The severity and timing of AEs indicates how well the treatment regimen was tolerated. Toxicities were evaluated using the common terminology criteria for adverse events (CTCAE) grading scheme.
| participants | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTCAE Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CTCAE Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CTCAE Grade 3 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 |
| CTCAE Grade 4 | 0 | 2 | 2 | 2 | 4 | 3 | 1 | 2 | 3 | 1 | 3 | 1 | 2 | 2 |
| CTCAE Grade 5 | 3 | 0 | 0 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 4 |
Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)
| participants | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incidence of Dose Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria; The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. Partial remission (PR). All of the criteria for CR had to be met, except that the bone marrow had to contain ≥ 5% but less than 25% blasts (or ≤ 50% of initial blast count), or \< 5% blasts in the presence of Auer rods or abnormal morphology.
| participants | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partial Remission | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
EFS was defined as the duration of time from randomisation to time of treatment failure (i.e. PD), relapse from CR, or death from any cause, whichever came first.
| days | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Event Free Survival (EFS) | 35.0 ± 15.6 | 122.3 ± 120.0 | 32.0 ± 1.0 | 117.5 ± 102.4 | 60.4 ± 52.6 | 62.0 ± 54.1 | 209.0 ± 315.8 | 65.0 ± 41.5 | 168.8 ± 219.3 | 62.7 ± 53.9 | 138.7 ± 183.2 | 48.5 ± 36.9 | 174.0 ± 67.2 | 30.0 ± 7.3 |
Relapse-free survival was defined only for patients who achieved CR/CRi and was measured from the date of attaining CR/CRi until the date of recurrence or death from any cause, whichever occurred first. Number of patients having relapse free survival are presented.
| participants | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relapse Free Survival | — | — | — | 1 | — | 1 | 1 | — | 1 | 1 | 1 | — | 2 | — |
Remission duration analysis was defined only for patients who achieved CR, and was measured from the date of attaining CR until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of the cause.
| days | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283+ 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remission Duration | — | — | — | 263.0 ± NA | — | 28.0 ± NA | 337.0 ± NA | — | 455.0 ± NA | — | 128.0 ± NA | — | 15.0 ± NA | — |
OS was defined for all patients that entered the trial, and measured from the date of randomization until death from any cause.
| days | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 122.8 ± 166.2 | 212.0 ± 55.1 | 71.3 ± 40.5 | 236.8 ± 225.5 | 148.7 ± 125.5 | 86.6 ± 58.1 | 236.8 ± 322.9 | 137.3 ± 121.7 | 198.2 ± 260.1 | 339.7 ± 364.8 | 175.7 ± 175.4 | 73.0 ± 31.3 | 294.7 ± 101.5 | 48.7 ± 17.9 |
Cmax (maximum measured concentration of BI 811283 in plasma) during Cycle 1
| nmol/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine- Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120mg (BI 811283+ Cytarabine)- Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of BI 811283 in Plasma) | 8.03 ± 32.3 | 64.10 ± 686.0 | 104.00 ± 321.0 | 153.00 ± 108.0 | 214.00 ± 38.8 | 272.00 ± 30.0 | 7.06 ± 10.0 | 66.10 ± 85.3 | 139.00 ± 33.8 | 499.00 ± 101.0 | 445.00 ± 71.0 | 631.00 ± 31.0 | 528.00 ± 40.5 | 1130.00 ± 53.3 |
AUC(0-inf) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) during Cycle 1
| nmol·h/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) | 177 ± 28.2 | 985 ± 311.0 | 1000 ± 40.7 | 2790 ± 130 | 4400 ± 62.9 | 5620 ± 27.9 | 192 ± 47.7 | 1490 ± 98.1 | 2840 ± 29.6 | 8870 ± 59.9 | 9770 ± 63.0 | 14100 ± 32.6 | 12800 ± 64.3 | 23200 ± 57.9 |
AUC0-tz (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) during Cycle 1
| nmol·h/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) | 169 ± 30.5 | 939 ± 328 | 2010 ± 207 | 2350 ± 105 | 2810 ± 135 | 5340 ± 27.2 | 156 ± 17.5 | 1450 ± 97.3 | 2730 ± 29.1 | 8680 ± 60.4 | 9260 ± 63.6 | 13700 ± 31.7 | 12100 ± 63.1 | 21700 ± 55.2 |
Cmax (maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1
| nmol/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A |
|---|---|---|---|---|---|---|
| Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State) | 8.02 ± 4.59 | 24.7 ± 18.5 | 43.3 ± 5.58 | 141 ± 52.2 | 213 ± 96.1 | 229 ± 67.9 |
AUC (0-inf, ss)(area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) at steady state during Cycle 1
| nmol·h/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A |
|---|---|---|---|---|---|---|
| AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State | 188 ± 12.7 | 615 ± 15.3 | NA ± NA | 4460 ± 41.8 | 5140 ± 105.0 | 4750 ± 58.1 |
AUC (0-tz,ss) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) at steady state during Cycle 1
| nmol·h/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A |
|---|---|---|---|---|---|---|
| AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State | 183 ± 14.3 | 597 ± 15.0 | 1620 ± 58.2 | 4330 ± 40.5 | 4340 ± 83.6 | 4820 ± 55.6 |
tmax (time from dosing to maximum measured concentration of BI 811283 in plasma) during Cycle 1
| hours | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma) | 24.0 (6.0 to 24.1) | 26.0 (6.0 to 48.0) | 25.0 (24.0 to 32.0) | 22.7 (6.0 to 24.1) | 6.0 (4.1 to 24.3) | 23.6 (5.9 to 24.5) | 23.9 (4.0 to 24.2) | 6.0 (6.0 to 6.0) | 24.1 (6.0 to 26.8) | 24.9 (23.6 to 32.0) | 6.0 (6.0 to 25.0) | 23.9 (23.9 to 24.1) | 5.9 (4.8 to 6.0) | 14.8 (3.9 to 26.1) |
tmax,ss (time from dosing to maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1
| hours | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A |
|---|---|---|---|---|---|---|
| Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State) | 23.9 (4.1 to 23.9) | 24.0 (4.0 to 24.0) | 6.0 (4.0 to 24.0) | 6.0 (4.1 to 24.0) | 6.0 (5.9 to 23.5) | 6.0 (4.0 to 23.8) |
Cmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
| ng/mL | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of Cytarabine in Plasma) | 53.2 ± 65.4 | 72.6 ± 31.0 | 49.0 ± 80.6 | 64.9 ± 49.5 | 61.9 ± 57.3 | 46.0 ± 54.1 | 46.3 ± 31.8 | 49.8 ± 58.1 | 55.0 ± 16.5 | 65.1 ± 44.5 | 49.4 ± 58.9 | 48.6 ± 88.4 | 49.0 ± 77.0 | 68.7 ± 33.1 |
Tmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
| hours | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma) | 0.50 (0.50 to 1.0) | 0.50 (0.50 to 1.0) | 0.92 (0.50 to 1.0) | 0.83 (0.50 to 1.4) | 0.48 (0.42 to 0.53) | 0.55 (0.50 to 1.5) | 0.50 (0.40 to 0.70) | 0.50 (0.50 to 0.50) | 0.58 (0.47 to 1.0) | 0.50 (0.43 to 0.67) | 0.50 (0.45 to 1.0) | 0.50 (0.47 to 0.50) | 0.48 (0.48 to 1.0) | 0.49 (0.48 to 0.57) |
AUC (0-inf) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
| ng·h/mL | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity) | 104 ± 31.4 | 122 ± 6.89 | 102 ± 31.5 | 85.4 ± 35.3 | 65.9 ± 42.5 | 68.1 ± 41.4 | 62.0 ± 24.1 | NA ± NA | NA ± NA | 71.2 ± 20.7 | 72.7 ± 23.6 | 75.5 ± 27.2 | 76.9 ± 19.5 | 76.8 ± 42.6 |
AUC (0-tz) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283
| ng·h/L | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) | 45.0 ± 156.0 | 66.9 ± 73.8 | 66.8 ± 57.6 | 71.8 ± 26.4 | 46.6 ± 51.2 | 42.3 ± 64.3 | 45.9 ± 20.0 | 33.9 ± 245.0 | 57.0 ± 18.2 | 60.2 ± 30.4 | 52.5 ± 38.8 | 52.1 ± 42.1 | 41.3 ± 87.2 | 51.6 ± 38.1 |
Pharmacodynamic monitoring: drug effect on leukaemia cells (e.g. polyploidy, histone H3 phosphorylation, morphologic changes). An evaluation of this secondary endpoint is not possible due to missing samples / samples of poor quality of the provided material.
No measurements were reported for this outcome.
The study protocol originally included a phase II part with a treatment arm in which Cytarabine was given alone, however the sponsor discontinued the clinical development of BI 811283, therefore the protocol was amended and the reference therapy arm was removed from the study protocol" -\> (Protocol Amendment 5, version 19 -May-2010, approved 28-Jun-2010). Since there was never a treatment arm in which Cytarabine was given alone; hence pharmacokinetics are not calculated.
No measurements were reported for this outcome.
Collected over Data from first treatment administration until cut-off date of 20 October 2011; up to 1239 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 3/4 (75%) | 4/4 (100%) |
| 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 2/3 (66.7%) | 3/3 (100%) |
| 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 3/3 (100%) | 3/3 (100%) |
| 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 4/4 (100%) | 4/4 (100%) |
| 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 6/7 (85.7%) | 7/7 (100%) |
| 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | — | 6/7 (85.7%) | 7/7 (100%) |
| 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 4/4 (100%) | 4/4 (100%) |
| 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 3/4 (75%) | 4/4 (100%) |
| 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 5/5 (100%) | 5/5 (100%) |
| 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 3/3 (100%) | 3/3 (100%) |
| 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 7/7 (100%) | 6/7 (85.7%) |
| 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 3/4 (75%) | 4/4 (100%) |
| 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 3/3 (100%) | 3/3 (100%) |
| 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | — | 5/6 (83.3%) | 6/6 (100%) |
| Event | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 1/3 | 2/4 | 2/7 | 0/7 | 3/4 | 1/4 | 1/5 | 1/3 | 2/7 | 2/4 | 2/3 | 2/6 |
| General physical health deteriorationGeneral disorders | 0/4 | 0/3 | 0/3 | 1/4 | 0/7 | 2/7 | 0/4 | 0/4 | 1/5 | 2/3 | 3/7 | 1/4 | 0/3 | 0/6 |
| PyrexiaGeneral disorders | 1/4 | 2/3 | 0/3 | 1/4 | 0/7 | 0/7 | 2/4 | 1/4 | 0/5 | 1/3 | 0/7 | 0/4 | 0/3 | 0/6 |
| C-reactive protein increasedInvestigations | 0/4 | 0/3 | 0/3 | 1/4 | 1/7 | 1/7 | 0/4 | 0/4 | 1/5 | 2/3 | 1/7 | 0/4 | 0/3 | 0/6 |
| Multi-organ failureGeneral disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/7 | 1/7 | 0/4 | 2/4 | 0/5 | 0/3 | 0/7 | 0/4 | 0/3 | 0/6 |
| PneumoniaInfections and infestations | 2/4 | 0/3 | 0/3 | 2/4 | 2/7 | 1/7 | 1/4 | 2/4 | 2/5 | 0/3 | 2/7 | 0/4 | 1/3 | 1/6 |
| SepsisInfections and infestations | 1/4 | 0/3 | 0/3 | 0/4 | 0/7 | 1/7 | 0/4 | 0/4 | 0/5 | 1/3 | 1/7 | 2/4 | 0/3 | 0/6 |
| LeukocytosisBlood and lymphatic system disorders | 0/4 | 0/3 | 0/3 | 0/4 | 1/7 | 0/7 | 0/4 | 0/4 | 0/5 | 1/3 | 0/7 | 0/4 | 0/3 | 0/6 |
| Acute myocardial infarctionCardiac disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/7 | 0/7 | 0/4 | 0/4 | 0/5 | 1/3 | 1/7 | 0/4 | 0/3 | 0/6 |
| Atrial fibrillationCardiac disorders | 0/4 | 0/3 | 0/3 | 0/4 | 0/7 | 0/7 | 0/4 | 0/4 | 0/5 | 1/3 | 0/7 | 0/4 | 0/3 | 0/6 |
| Event | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/4 | 2/3 | 1/3 | 1/4 | 5/7 | 5/7 | 1/4 | 2/4 | 1/5 | 3/3 | 3/7 | 1/4 | 3/3 | 3/6 |
| LeukopeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 1/3 | 1/4 | 4/7 | 5/7 | 1/4 | 1/4 | 1/5 | 1/3 | 3/7 | 2/4 | 3/3 | 2/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/3 | 0/4 | 1/7 | 1/7 | 0/4 | 0/4 | 1/5 | 1/3 | 1/7 | 0/4 | 3/3 | 2/6 |
| NauseaGastrointestinal disorders | 2/4 | 2/3 | 0/3 | 2/4 | 3/7 | 4/7 | 1/4 | 1/4 | 3/5 | 2/3 | 1/7 | 3/4 | 3/3 | 2/6 |
| FatigueGeneral disorders | 0/4 | 1/3 | 2/3 | 1/4 | 3/7 | 2/7 | 1/4 | 2/4 | 1/5 | 3/3 | 4/7 | 2/4 | 1/3 | 2/6 |
| FallInjury, poisoning and procedural complications | 0/4 | 0/3 | 0/3 | 2/4 | 1/7 | 0/7 | 0/4 | 0/4 | 2/5 | 3/3 | 2/7 | 0/4 | 1/3 | 1/6 |
| Blood potassium decreasedInvestigations | 0/4 | 0/3 | 0/3 | 1/4 | 5/7 | 4/7 | 0/4 | 0/4 | 0/5 | 1/3 | 3/7 | 1/4 | 3/3 | 1/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/3 | 1/3 | 0/4 | 2/7 | 4/7 | 1/4 | 2/4 | 1/5 | 3/3 | 5/7 | 0/4 | 0/3 | 2/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 2/3 | 1/3 | 2/4 | 2/7 | 2/7 | 2/4 | 3/4 | 3/5 | 2/3 | 2/7 | 2/4 | 2/3 | 2/6 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/4 | 1/7 | 2/7 | 3/4 | 0/4 | 1/5 | 1/3 | 3/7 | 0/4 | 1/3 | 1/6 |
68 participants were randomised, and 64 were treated with the study treatment hence the number of participants differs from the number of participants that started in the participant flow.
| Age, Continuous(years) | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 76.0 ± 5.8 | 71.3 ± 2.5 | 79.3 ± 8.4 | 77.5 ± 4.0 | 67.4 ± 9.3 | 72.3 ± 5.1 | 74.3 ± 4.1 | 73.5 ± 6.6 | 79.0 ± 4.4 | 78.3 ± 4.0 | 72.3 ± 4.4 | 69.5 ± 11.8 | 63.3 ± 5.1 | 63.3 ± 5.6 | 72.2 ± 7.6 |
| Sex: Female, Male(Participants) | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 2 | 4 | 3 | 1 | 3 | 2 | 2 | 2 | 2 | 0 | 2 | 30 |
| Male | 1 | 1 | 1 | 2 | 3 | 4 | 3 | 1 | 3 | 1 | 5 | 2 | 3 | 4 | 34 |
The record gives a start of May 2008, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year 2 months after primary completion. A results delay was requested in Apr 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytarabine